Alpha Cognition Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Alpha Cognition's estimated annual revenue is currently $703.5k per year.(i)
  • Alpha Cognition's estimated revenue per employee is $100,500

Employee Data

  • Alpha Cognition has 7 Employees.(i)
  • Alpha Cognition grew their employee count by -12% last year.

Alpha Cognition's People

NameTitleEmail/Phone
1
Co-Founder & Chief Scientific Officer at Alpha Cognition Inc.Reveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Commercial OfficerReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
SVP, Product DevelopmentReveal Email/Phone
6
Document Control/Logistics ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$33.4M166-10%N/AN/A
#2
$68.8M27418%$942.6MN/A
#3
$23.5M1170%N/AN/A
#4
$1.6M1645%$3.7MN/A
#5
$0.7M70%N/AN/A
#6
$1.5M1515%N/AN/A
#7
$1.4M1417%N/AN/A
#8
$0.7M7-12%N/AN/A
#9
$17.7M8824%N/AN/A
#10
$4.6M23-56%N/AN/A
Add Company

What Is Alpha Cognition?

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

keywords:N/A

N/A

Total Funding

7

Number of Employees

$703.5k

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.1M70%N/A
#2
$0.5M7N/AN/A
#3
$0.5M7N/AN/A
#4
$3.5M7-12%N/A
#5
$0.5M7N/AN/A